Yes. Under the new ACIP recommendations published in January 2022, adults age 19 through 64 who have already received a dose of PCV13 (as previously recommended for those with immunocompromising conditions [including asplenia], CSF leak, or cochlear implant) should complete the immunization schedule that was recommended before the introduction of PCV15 and PCV20.
Adults age 19 through 64 who have immunocompromising conditions, a CSF leak, or a cochlear implant and who have already received a dose of PCV13 should receive a dose of PPSV23 at least 8 weeks later. Those who are immunocompromised should then receive a second dose of PPSV23 at least 5 years following the first dose; if younger than 65 at the time of dose 2, they should receive a third dose of PPSV23 at least 5 years later and after turning 65.
If PPSV23 is unavailable when vaccination is due and PCV20 is available, PCV20 may be used. If PCV20 is administered, no additional doses of pneumococcal vaccine are recommended.
Last reviewed:
July 26, 2022
That is not necessary. Although PPSV23 is recommended, CDC has stated that PCV20 may be used if PPSV23 is unavailable.
Last reviewed:
July 26, 2022
At this time, ACIP does not recommend revaccination with PPSV23 for adults younger than 65 who are at the highest risk of pneumococcal disease (including those with asplenia) who receive PCV15 (Vaxneuvance) followed by PPSV23.
If an adult patient with asplenia receives PCV13 (Prevnar 13) followed by PPSV23, ACIP recommends continuing the previously recommended schedule for patients with immunocompromising conditions (including asplenia) who receive that vaccine combination. In that case, the patient would be revaccinated with PPSV23 at least 5 years following the first dose. If dose 2 is administered when the patient is younger than 65, then dose 3 is due at least 5 years later and after the patient turns 65.
If an adult patient with asplenia receives a dose of PCV20, ACIP does not recommend further doses of any pneumococcal vaccine.
Last reviewed:
July 26, 2022
A second PPSV23 given 5 years after the first dose is recommended for people age 19 through 64 years who were vaccinated with PCV13 and PPSV23 and who have one of the following:
- functional or anatomic asplenia (including persons with sickle cell disease or splenectomy patients)
- chronic renal failure (including dialysis patients) or nephrotic syndrome
- immunocompromise (including HIV infection)
- leukemia, lymphoma, Hodgkin disease, multiple myeloma, generalized malignancy
- immunosuppressive therapy (including long-term systemic corticosteroids or radiation therapy)
- solid organ transplant
Last reviewed:
July 26, 2022
Yes, but only if they have already received PCV13. If they have not received any PCV product, or their history of PCV vaccination is unknown, they may receive a single dose of either PCV15 or PCV20. If they have already received either PCV20 or PCV15, then no additional PPSV23 doses are needed.
Last reviewed:
July 26, 2022
No. ACIP does not recommend revaccination with PPSV23 for any adult who has received a dose of PPSV23 after turning 65. The patient may, however, receive either PCV15 or PCV20 if they have not already received PCV13.
Last reviewed:
July 26, 2022
